SAN DIEGO, Nov. 8, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2017
London Healthcare Conference at 11:20 a.m.
GMT (6:20 a.m. ET) on
Thursday, Nov. 16, 2017, in
London. Kevin Gorman, CEO of Neurocrine Biosciences,
will present at the conference.
The live presentation will be webcast and may be accessed on the
Company's website at http://www.neurocrine.com. A replay of the
presentation will be available on the website approximately one
hour after the conclusion of the event and will be archived for one
month.
About Neurocrine Biosciences, Inc.
Neurocrine
Biosciences is a San Diego based biotechnology
company focused on neurologic, psychiatric and endocrine related
disorders. The Company markets INGREZZA® (valbenazine)
capsules in the United States for the treatment of adults
with tardive dyskinesia. INGREZZA is a novel, selective
vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the
first FDA approved product indicated for the treatment of adults
with tardive dyskinesia. The Company's three late-stage
clinical programs are: elagolix, a gonadotropin-releasing hormone
antagonist for women's health that is partnered with AbbVie
Inc.; opicapone, a novel, once-daily, peripherally-acting,
highly-selective catechol-o-methyltransferase inhibitor under
investigation as adjunct therapy to levodopa in Parkinson's
patients; and INGREZZA, a novel, once-daily, selective VMAT2
inhibitor under investigation for the treatment of Tourette
syndrome.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
View original
content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-jefferies-2017-london-healthcare-conference-300551499.html
SOURCE Neurocrine Biosciences, Inc.